Accepted palliative antirheuma

United States a randomized, double-blind, placebo-controlled study, included 97 cases of rheumatoid arthritis (RA)   patients. 1th group 20 patients received 1 LY2439821 intravenous or placebo treatment, follow-up to 8 weeks.　　　　77 cases of 2nd group patients every 2 week 1, total 5 LY2439821 treated with intravenous or placebo, overall assessment lasts 16 weeks. Found that, compared with the placebo group, United LY2439821 in the treatment of intravenous injection of 0.2 mg/kg, 2.0 mg/kg, and all group 10th week of disease activity index (DAS28) scoring changes significantly greater (p ≤ 0.05), these differences in the treatment of early 1th week is more obvious. www.cmt.com.cn